KURA ONCOLOGY, INC. (NASDAQ:KURA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On January 3, 2017, the Board of Directors (the Board) of Kura
Oncology, Inc. (the Company), upon recommendation of the
Nominating and Corporate Governance Committee of the Board (the
Nominating Committee), appointed Steven H. Stein, M.D. (i) as a
director of the Company, with a term of office expiring at the
next annual meeting of stockholders, and (ii) as a member of each
of the Nominating Committee and the Compensation Committee of the
Board (the Compensation Committee).There are no arrangements or
understandings between Dr. Stein and any other person to which he
was selected as a director. In addition, there are no
transactions in which Dr. Stein has an interest that would
require disclosure under Item 404(a) of Regulation S-K.
to the Companys Amended and Restated Non-Employee Director
Compensation Policy (the Compensation Policy), Dr. Stein (i) will
receive an annual cash retainer of $35,000 for service on the
Board, $3,750 for service on the Nominating Committee and $5,000
for service on the Compensation Committee and (ii) was granted on
the date of his appointment an option to purchase (a) 30,000
shares of the Companys common stock, which vests annually over a
three year period, and (b) 3,333 shares of the Companys common
stock, which vests in full on the one year anniversary of the
date of grant. The Compensation Policy also provides for further
automatic annual option grants to purchase 10,000 shares of the
Companys common stock on the date of each annual meeting of
stockholders, which vest in full on the one year anniversary of
the date of grant. Each of the option grants described above will
vest in full in the event of a change in control (as defined in
the Companys equity incentive plan). Dr. Stein has also entered
into the Companys standard form of Indemnification Agreement.
The Company issued a press release announcing the appointment of
Dr. Stein, a copy of which is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press Release issued by Kura Oncology, Inc. on January 3, |
About KURA ONCOLOGY, INC. (NASDAQ:KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. KURA ONCOLOGY, INC. (NASDAQ:KURA) Recent Trading Information
KURA ONCOLOGY, INC. (NASDAQ:KURA) closed its last trading session up +0.40 at 6.00 with shares trading hands.